GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acelyrin Inc (NAS:SLRN) » Definitions » Cash Conversion Cycle

Acelyrin (Acelyrin) Cash Conversion Cycle : 0.00 (As of Mar. 2024)


View and export this data going back to 2023. Start your Free Trial

What is Acelyrin Cash Conversion Cycle?

Cash Conversion Cycle is one of several measures of management effectiveness. It equals Days Sales Outstanding + Days Inventory - Days Payable.

Acelyrin's Days Sales Outstanding for the three months ended in Mar. 2024 was .
Acelyrin's Days Inventory for the three months ended in Mar. 2024 was .
Acelyrin's Days Payable for the three months ended in Mar. 2024 was .
Therefore, Acelyrin's Cash Conversion Cycle (CCC) for the three months ended in Mar. 2024 was 0.00.


Acelyrin Cash Conversion Cycle Historical Data

The historical data trend for Acelyrin's Cash Conversion Cycle can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acelyrin Cash Conversion Cycle Chart

Acelyrin Annual Data
Trend Dec21 Dec22 Dec23
Cash Conversion Cycle
- - -

Acelyrin Quarterly Data
Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cash Conversion Cycle Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Acelyrin's Cash Conversion Cycle

For the Biotechnology subindustry, Acelyrin's Cash Conversion Cycle, along with its competitors' market caps and Cash Conversion Cycle data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Acelyrin's Cash Conversion Cycle Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Acelyrin's Cash Conversion Cycle distribution charts can be found below:

* The bar in red indicates where Acelyrin's Cash Conversion Cycle falls into.



Acelyrin Cash Conversion Cycle Calculation

Cash Conversion Cycle (CCC) measures how fast a company can convert cash on hand into even more cash on hand. This metric looks at the amount of time needed to sell inventory, the amount of time needed to collect receivables and the length of time the company is afforded to pay its bills without incurring penalties.

Cash Conversion Cycle is one of several measures of management effectiveness.

Acelyrin's Cash Conversion Cycle for the fiscal year that ended in Dec. 2023 is calculated as

Cash Conversion Cycle=Days Sales Outstanding +Days Inventory-Days Payable
=+-
=0.00

Acelyrin's Cash Conversion Cycle for the quarter that ended in Mar. 2024 is calculated as:

Cash Conversion Cycle=Days Sales Outstanding+Days Inventory-Days Payable
=+-
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Acelyrin  (NAS:SLRN) Cash Conversion Cycle Explanation

Generally, the lower this number is, the better for the company. Although it should be combined with other metrics (such as ROE % and ROA %), it can be especially useful for comparing close competitors, because the company with the lowest CCC is often the one with better management.


Be Aware

CCC is most effective with retail-type companies, which have inventories that are sold to customers. Consulting businesses, software companies and insurance companies are all examples of companies for whom this metric is meaningless.

The CCC is one of several tools that can help you evaluate management, especially if it is calculated for several consecutive time periods and for several competitors. Decreasing or steady CCCs are good, while rising ones should motivate you to dig a bit deeper.


Acelyrin Cash Conversion Cycle Related Terms

Thank you for viewing the detailed overview of Acelyrin's Cash Conversion Cycle provided by GuruFocus.com. Please click on the following links to see related term pages.


Acelyrin (Acelyrin) Business Description

Traded in Other Exchanges
N/A
Address
4149 Liberty Canyon Road, Agoura Hills, CA, USA, 91301
Acelyrin Inc is a late-stage clinical biopharmaceutical company. It is focused on providing patients life-changing new treatment options by identifying, acquiring, and accelerating development and commercialization of promising drug candidates.
Executives
Shao-lee Lin director, officer: Chief Executive Officer C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Gil M Labrucherie officer: Interim CFO 150 INDUSTRIAL ROAD, SAN CARLOS CA 94070
Beth C Seidenberg director, 10 percent owner
Henry O Gosebruch director 1 N. WAUKEGAN ROAD, NORTH CHICAGO IL 60064-6092
Mardi Dier officer: CFO and CBO C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Mina Kim officer: Chief Legal & Admin. Officer C/O ACELYRIN, INC., 4149 LIBERTY CANYON RD., AGOURA HILLS CA 91301
Ronald Oyston officer: Chief People Officer C/O ACELYRIN, INC., 4149 LIBERTY CANYON ROAD, AGOURA HILLS CA 91301
Paul Peloso officer: Chief Medical Officer C/O ACELYRIN, INC., 4149 LIBERTY CANYON ROAD, AGOURA HILLS CA 91301
Dawn Svoronos director C/O MEDIVATION, INC., 525 MARKET ST., 36TH FLOOR, SAN FRANCISCO CA 94105
Daniel J. Becker director C/O NEW LEAF VENTURE PARTNERS, TIMES SQ TOWER, 7 TIMES SQ, STE 3502, NEW YORK NY 10036
Westlake Biopartners Fund Ii, L.p. 10 percent owner 3075 TOWNSGATE ROAD, SUITE 140, WESTLAKE VILLAGE CA 91361
Ayurmaya Capital Management Company, Lp director, 10 percent owner, other: See Remarks 1000 WINTER STREET, SUITE 4500, WALTHAM MA 02451
Sean E Harper 10 percent owner AMGEN INC., ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA 91320-1799
Melanie Gloria officer: Chief Operating Officer C/O ACELYRIN, INC., 4149 LIBERTY CANYON ROAD, AGOURA HILLS CA 91301
Westlake Biopartners Gp Ii, Llc 10 percent owner 3075 TOWNSGATE ROAD, SUITE 140, WESTLAKE VILLAGE CA 91361

Acelyrin (Acelyrin) Headlines

From GuruFocus